Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer

Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer

Owing to incurable castration-resistant prostate cancer (CRPC) ultimately developing after treating with androgen deprivation therapy (ADT), it is vital to devise new therapeutic strategies to treat CRPC. Treatments that target programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD...

Full description

Bibliographic Details
Main Authors: Xumin Zhou, Libin Zou, Hangyu Liao, Junqi Luo, Taowei Yang, Jun Wu, Wenbin Chen, Kaihui Wu, Shengren Cen, Daojun Lv, Fangpeng Shu, Yu Yang, Chun Li, Bingkun Li, Xiangming Mao
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:Acta Pharmaceutica Sinica B
Subjects:
HnRNP L
PD-L1
YY1
Ferroptosis
Immune escape
Immune checkpoint blockade
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383521002653

Similar Items

Similar Items